CRP and metabolic dysfunction-associated steatotic liver disease: The multiple logistic regression models showed that NAFLD wild type treated patients had higher possibilities of useful therapeutic outcome on insulinemia (RR: 6.876, 95% CI: 1.748–27.042, p = 0.006), HOMA-IR (RR: 11.341, 95% CI: 2.687–47.857, p = 0.001), ALT (RR: 7.198, 95% CI: 1.755–29.530, p = 0.006), CRP (RR: 12.254, 95% CI: 2.627–57.166, p = 0.001), and TBARS (RR: 6.912, 95% CI: 1.693–28.210, p = 0.007) in comparison to the patients carrying at least one of the abovementioned mutations.